# US 2002/0058627 A1 · Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058627 A1
- Document ID: US20020058627A1
- Status: Published application
- Kind: A1
- Application number: 09/989,476
- Filed: 2001-11-19
- Published: 2002-05-16
- Earliest claimed: 1994-11-18
- Assignees: Neurocrine Biosciences, Inc.
- Inventors: Lawrence Steinman; Nicholas Ling; Paul J. Conlon; Amitabh Gaur
- Web page: https://patentgrep.com/patent/US20020058627A1

## CPC

- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.

## Claims

### Claim 1

A peptide analogue comprising amino acid residues 87-99 of human myelin basic protein, wherein lysine at position 91 is altered to another amino acid.

### Claim 2 (depends on 1)

The peptide analogue of claim 1 wherein the amino acid at position 91 is altered to a non-conservative amino acid.

### Claim 3 (depends on 1)

The peptide analogue of claim 1 wherein the amino acid at position 91 is altered with an amino acid selected from the group consisting of D-lysine, alanine, glycine, glutamic acid, phenylalanine, arginine, asparagine, histidine, leucine and serine.

### Claim 4 (depends on 1)

The peptide analogue of claim 1 wherein the amino acid at position 91 is altered to D-lysine.

### Claim 5 (depends on 1)

The peptide analogue of claim 1 wherein the alteration at position 91 results in reduced expression of TNF-α from MBP-reactive T cells.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising a peptide analogue according to claim 1 in combination with a physiologically acceptable carrier or diluent.

### Claim 7

A method of treating multiple sclerosis, comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising peptide analogue comprising amino acid residues 87-99 of myelin basic protein, wherein the L-lysine residue at position 91 is replaced by another amino acid, in combination with a physiologically acceptable carrier or diluent.

### Claim 8 (depends on 7)

The method of claim 7 wherein the amino acid at position 91 is altered with an amino acid selected from the group consisting of D-lysine, alanine, glycine, glutamic acid, phenylalanine, arginine, asparagine, histidine, leucine and serine.

### Claim 9 (depends on 7)

The method of claim 7 wherein the amino acid at position 91 is altered to a non-conservative amino acid.

### Claim 10 (depends on 7)

The method of claim 7 wherein the amino acid at position 91 is altered to D-lysine.

### Claim 11 (depends on 7)

The method of claim 7 wherein the alteration at position 91 results in reduced expression of TNF-α from MBP-reactive T cells.
